Smad7 selectively interferes with different pathways of activin signaling and inhibits erythroid leukemia cell differentiation

Blood

Volumn 95, Issue 11, 2000, Pages 3371-3379

  Kitamura, Koki ^a   Aota, Shin Ichi ^a   Sakamoto, Ruriko ^a   Yoshikawa, Shun Ichi ^a   Okazaki, Kenji ^a  

^a BIOMOL ENG RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; PROTEIN SERINE THREONINE KINASE; RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ERYTHROID CELL; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0034210252     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.11.3371     Document Type: Article

References (92)

1. Wall NA, Hogan BL. TGF-β related genes in development. Curr Opin Genet Dev. 1994;4:517-522.
2. Massagué J, Attisano L, Wrana JL. The TGF-β family and its composite receptors. Trends Cell Biol. 1994;4:172-178.
3. Raftery LA, Twombly V, Wharton K, Gelbart WM. Genetic screens to identify elements of the decapenlaplegic signaling pathway in Drosophila. Genetics. 1995;139:241-254.
4. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics. 1995;139:1347-1358.
5. Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465-471.
6. Massagué J. TGF-β signal transduction. Annu Rev Biochem. 1998;67:753-791.
7. Lechleider RJ, de Caestecker MP, Dehejia A, Polymeropoulos MH, Roberts AB. Serine phosphorylation, chromosomal localization, and transforming growth factor-β signal transduction by human bsp-1. J Biol Chem. 1996;271:17,617-17,620.
8. Yingling JM, Das P, Savage C, Zhang M, Padgett RW, Wang XF. Mammalian dwarfins are phosphorylated in response to transforming growth factor β and are implicated in control of cell growth. Proc Natl Acad Sci U S A. 1996;93:8940-8944.
9. Graff JM, Bansal A, Melton DA. Xenopus Mad proteins transduce distinct subsets of signals for the TGF-β superfamily. Cell. 1996;85:479-487.
10. Baker JC, Harland RM. A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway. Genes Dev. 1996;10:1880-1889.
11. Thomsen GH. Xenopus mothers against decapentaplegic is an embryonic ventralizing agent that acts downstream of the BMP-2/4 receptor. Development. 1996;122:2359-2366.
12. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
13. Bruno E, Horrigan SK, Van Den Berg D, et al. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-β on human hematopoiesis. Blood. 1998;91:1917-1923.
14. Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGF-β superfamily. Nature. 1997;389:622-626.
15. Hata A, Lagna G, Massagué J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev. 1998;12:186-197.
16. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling. Cell. 1997;89:1165-1173.
17. Nakao A, Afrakhte M, Morén A, et al. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling. Nature. 1997;389:631-635.
18. Nakayama T, Snyder MA, Grewal SS, Tsuneizumi K, Tabata T, Christian JL. Xenopus Smad8 acts downstream of BMP-4 to modulate its activity during vertebrate embryonic patterning. Development. 1998;125:857-867.
19. Casellas R, Brivanlou AH. Xenopus Smad7 inhibits both the activin and BMP pathways and acts as a neural inducer. Dev Biol. 1998;198:1-12.
20. Bhushan A, Chen Y, Vale W. Smad7 inhibits mesoderm formation and promotes neural cell fate in Xenopus embryos. Dev Biol. 1998;200:260-268.
21. Vale W, Rivier J, Vaughan J, et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature. 1986; 321:776-779.
22. Ling N, Ying SY, Ueno N, et al. Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin. Nature. 1986;321:779-782.
23. Vale W, Hsueh A, River C, Yu J. The inhibin/activin family of hormones and growth factors. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and their Receptors. Part II. Berlin, Germany: Springer-Verlag; 1990:211-248.
24. DePaolo LV, Bicsak TA, Erickson GF, Shimasaki S, Ling N. Follistatin and activin: a potential intrinsic regulatory system within diverse tissues. Proc Soc Exp Biol Med. 1991;198:500-512.
25. Smith JC. Mesoderm-inducing factors in early vertebrate development. EMBO J. 1993;12:4463-4470.
26. Murata M, Onomichi K, Eto Y, Shibai H, Muramatsu M. Expression of erythroid differentiation factor (EDF) in Chinese hamster ovary cells. Biochem Biophys Res Commun. 1988;151:230-235.
27. Eto Y, Tsuji T, Takezawa M, Takano S, Yokogawa Y, Shibai H. Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1. Biochem Biophys Res Commun. 1987;142:1095-1103.
28. Yu J, Shao LE, Lemas V, et al. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature. 1987;330:765-767.
29. Attisano L, Wrana JL, Montalvo E, Massagué J. Activation of signalling by the activin receptor complex. Mol Cell Biol. 1996;16:1066-1073.
30. Lebrun JJ, Vale WW. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol Cell Biol. 1997;17:1682-1691.
31. Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL. Identification of human activin and TGF-β type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 1993;75:671-680.
32. Tsuchida K, Mathews LS, Vale WW. Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor. Proc Natl Acad Sci U S A. 1993;90:11,242-11,246.
33. Cárcamo J, Weis FM, Ventura F, et al. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol. 1994;14:3810-3821.
34. Ebner R, Chen RH, Lawler S, Zioncheck T, Derynck R. Determination of type I and specificity by the type II receptors for TGF-β or activin. Science. 1993;262:900-902.
35. ten Dijke P, Ichijo H, Franzén P, et al. Activin receptor-like kinases: a novel subclass of cell surface receptors with predicted serine/threonine kinase activity. Oncogene. 1993;8:2879-2887.
36. ten Dijke P, Yamashita H, Ichijo H, et al. Characterization of type I receptors for transforming growth factor-β and activin. Science. 1994;264: 101-104.
37. Mathews LS, Vale WW. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell. 1991;65:973-982.
38. Attisano L, Wrana JL, Cheifetz S, Massagué J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell. 1992;68: 97-108.
39. Mathews LS, Vale WW, Kintner CR. Cloning of a second type of activin receptor and functional characterization in Xenopus embryos. Science. 1992;255:1702-1705.
40. Yamashita H, ten Dijke P, Huylebroeck D, et al. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol. 1995;130:217-226.
41. Armes NA, Smith JC. The ALK-2 and ALK-4 activin receptors transduce distinct mesoderm-inducing signals during early Xenopus development but do not co-operate to establish thresholds. Development. 1997;124:3797-3804.
42. Owens RB, Smith HS, Hackett AJ. Epithelial cell cultures from normal glandular tissue of mice. J Natl Cancer Inst. 1974;53:261-269.
43. Ogawa M, Nishikawa S, Ikuta K, et al. B cell ontogeny in murine embryo studied by a culture system with the monolayer of a stromal cell clone, ST2: B cell progenitor develops first in the embryonal body rather than in the yolk sac. EMBO J. 1988;7:1337-1343.
44. Ebner R, Chen RH, Shum L, et al. Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. Science. 1993;260: 1344-1348.
45. Verschueren K, Dewulf N, Goumans MJ, et al. Expression of type I and type IB receptors for activin in midgestation mouse embryos suggests distinct functions in organogeresis. Mech Dev. 1995;52:109-123.
46. Okazaki K, Sagata N. The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. EMBO J. 1995;14:5048-5059.
47. Wieser R, Wrana JL, Massagué J. GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 1995;14:2199-2208.
48. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
49. Boer PH, Potten H, Adra CN, Jardine K, Mullhofer G, McBurney MW. Polymorphisms in the coding and noncoding regions of murine Pgk-1 alleles. Biochem Genet. 1990;28:299-308.
50. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993;90:8392-8396.
51. Konkel DA, Tilghman SM, Leder P. The sequence of the chromosomal mouse β-globin major gene: homologies in capping, splicing and poly(a) sites. Cell. 1978;15:1125-1132.
52. Like B, Massagué J. The antiproliferative effect of type β transforming growth factor occurs at a level distal from receptors for growth-activating factors. J Biol Chem. 1986;261:13,426-13,429.
53. Inge TH, McCoy KM, Susskind BM, Barrett SK, Zhao G, Bear HD. Immunomodulatory effects of transforming growth factor-β on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes. J Immunol. 1992; 148:3847-3856.
54. Brosh N, Sternberg D, Honigwachs-Sha'anani J, et al. The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11: identification as a stroma-derived activin A. J Biol Chem. 1995;270:29,594-29,600.
55. Yamada R, Suzuki T, Hashimoto M, Eto Y, Shiokawa K, Muramatsu M. Induction of differentiation of the human promyelocytic cell line HL-60 by activin/EDF. Biochem Biophys Res Commun. 1992;187:79-85.
56. Iwasaki S, Tsuruoka N, Hattori A, Sato M, Tsujimoto M, Kohno M. Distribution and characterization of specific cellular binding proteins for bone morphogenetic protein-2. J Biol Chem. 1995;270: 5476-5482.
57. Okabe-Kado J, Honma Y, Hozumi M. Inhibition by vitamin D3 of erythroid differentiation of human leukemia line cells induced by transforming growth factor β or erythroid differentiation factor (activin A). Leuk Res. 1991;15:721-726.
58. Wrana JL, Attisano L, Cárcamo J, et al. TGF-β signals through a heteromeric protein kinase receptor complex. Cell. 1992;71:1003-1014.
59. McBurney MW, Sutherland LC, Adra CN, Leclair B, Rudnicki MA, Jardine K. The mouse Pgk-1 gene promoter contains an upstream activator sequence. Nucleic Acids Res. 1991;19:5755-5761.
60. Martens JW, de Winter JP, Timmerman MA, et al. Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells. Endocrinology. 1997;138:2928-2936.
61. Franzén P, ten Dijke P, Ichijo H, et al. Cloning of a TGF-β type I receptor that forms a heteromeric complex with the TGF-β type II receptor. Cell. 1993;75:681-692.
62. Feng XH, Derynck R. Ligand-independent activation of transforming growth factor (TGF) β signaling pathways by heteromeric cytoplasmic domains of TGF-β receptors. J Biol Chem. 1996; 271:13,123-13,129.
63. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and their Receptors. Part I. Berlin, Germany: Springer-Verlag; 1990:419-472.
64. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996;10:1580-1594.
65. Ishisaki A, Yamato K, Nakao A, et al. Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells. J Biol Chem. 1998;273:24,293-24,296.
66. Ishisaki A, Yamato K, Hashimoto S, et.al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem. 1999;274:13,637-13,642.
67. Broxmeyer HE, Lu L, Cooper S, Schwall RH, Mason AJ, Nikolics K. Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin. Proc Natl Acad Sci U S A. 1988;85:9052-9056.
68. Shiozaki M, Sakai R, Tabuchi M, et al. Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis. Proc Natl Acad Sci U S A. 1992; 89:1553-1556.
69. Mizuguchi T, Kosaka M, Saito S. Activin A suppresses proliferation of interleukin-3-responsive granulocyte-macrophage colony-forming progenitors and stimulates proliferation and differentiation of interteukin-3-responsive erythroid burst-forming progenitors in the peripheral blood. Blood. 1993;81:2891-2897.
70. Nakao K, Kosaka M, Saito S. Effects of erythroid differentiation factor (EDF) on proliferation and differentiation of human hematopoietic progenitors. Exp Hematol. 1991;19:1090-1095.
71. Shao L, Frigon NL Jr, Young AL, et al. Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood. 1992;79: 773-781.
72. Ikawa Y, Aida M, Inoue Y. Isolation and characterization of high and low differentiation-inducible Friend leukemia lines. Gann. 1976;67:767-770.
73. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975;45:321-334.
74. Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science. 1982;216:1233-1235.
75. Topper JN, Cai J, Qiu Y, et al. Vascular MADs: two newel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci U S A. 1997;94:9314-9319.
76. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol. 1992;119:1017-1021.
77. Eppert K, Scherer SW, Ozcelik H. et al. Madr2 maps to 18q21 and encodes a TGF-β-regulated Mad-related protein that is functionally mutated in colorectal carcinoma. Cell. 1996;86:543-552.
78. Riggins GJ, Thiagalingam S, Rozenblum E, et al. Mad-related genes in the human. Nat Genet. 1996;13:347-349.
79. Hata A, Lo RS, Wotton D, Lagna G, Massagué J. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature. 1997;388:82-87.
80. Smith JC, Price BMJ, Green JBA, Weigel D, Herrmann BG. Expression of a Xenopus homolog of Brachyury (T) is an immediate-early response to mesoderm induction. Cell. 1991;67:79-87.
81. Green JB, Smith JC. Graded changes in dose of a Xenopus activin A homologue elicit stepwise transitions in embryonic cell fate. Nature. 1990; 347:391-394.
82. Gurdon JB, Harger P, Mitchell A, Lemaire P. Activin signalling and response to a morphogen gradient. Nature. 1994;371:487-492.
83. Klein PS, Melton DA. Hormonal regulation of embryogenesis: the formation of mesoderm in Xenopus laevis. Endocr Rev. 1994;15:326-341.
84. Tsuchida K, Vaughan JM, Wiater E, Gaddy-Kurten D, Vale WW. Inactivation of activin-dependent transcription by kinase-deficient activin receptors. Endocrinology. 1995;136:5493-5503.
85. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell. 1996;87:1215-1224.
86. Zhang Y, Feng XH, Wu RY, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature. 1996;383: 168-172.
87. Chen X, Rubock MJ, Whitman M. A transcriptional partner for MAD proteins in TGF-β signalling. Nature. 1996;383:691-696.
88. Chen Y, Lebrun JJ, Vale W. Regulation of transforming growth factor β- and activin-induced transcription by mammalian Mad proteins. Proc Natl Acad Sci U S A. 1996;93:12,992-12.997.
89. Lagna G, Hata A, Hemmati-Brivanlou A, Massagué J. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature. 1996;383:832-836.
90. Labbé E, Silvestri C, Hoodless PA, Wrana JL, Attisano L. Smad2 and Smad3 positively and negatively regulate TGF β-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell. 1998;2:109-120.
91. Kretzschmar M, Liu F, Hata A, Doody J, Massagué J. The TGF-β family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev. 1997; 11:984-995.
92. Chen Y, Bhushan A, Vale W. Smad8 mediates the signaling of the ALK-2 receptor serine kinase. Proc Natl Acad Sci U S A. 1997;94:12,938-12,943.